Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.65 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | USP20 | Q9Y2K6 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22693 | 1.00 | NFE2L2 (0.65) | NFE2L2ENPP2PTGS1PTGS2NQO2 | |
| SCHEMBL31350 | 1.00 | NFE2L2 (0.65) | NFE2L2ENPP2PTGS1PTGS2NQO2 | |
| SCHEMBL700537 | 0.80 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL700536 | 0.80 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL31317689 | 0.80 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL2319722 | 0.80 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL2319724 | 0.80 | NFE2L2 (0.65) | NFE2L2PTGS1PTGS2NQO2FBP1 | |
| SCHEMBL525893 | 0.79 | NFE2L2 (0.58) | NFE2L2PTGS1PTGS2NQO2USP20 | |
| SCHEMBL8084015 | 0.77 | NFE2L2 (0.61) | NFE2L2PTGS1PTGS2NQO2USP20 | |
| SCHEMBL9849735 | 0.76 | NFE2L2 (0.91) | NFE2L2PTGS1PTGS2NQO2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119708027-A | Method for preparing boronated carbonyl derivative | 中国科学院大连化学物理研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-111606824-B | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2023-03-14 | — | — | CN | claimed |
| CN-111606824-A | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2020-09-01 | — | — | CN | claimed |
| CN-116135861-A | Method for preparing boronated carbonyl derivative from alpha, beta-unsaturated carbonyl derivative | 中国科学院大连化学物理研究所 | 2023-05-19 | — | — | CN | disclosed |
| CN-111606824-B | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2023-03-14 | — | — | CN | disclosed |
| EP-3553097-B1 | COPOLYMER AND OPTICAL FILM USING SAME | TOSOH CORP (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-11225540-B2 | Copolymer and optical film using same | TOSOH CORPORATION (JP) | 2022-01-18 | — | — | US | disclosed |
| CN-110248971-B | Copolymer and optical film using the same | 东曹株式会社 | 2021-11-02 | — | — | CN | disclosed |
| CN-111606824-A | Beta-amino nitrile compound and preparation method thereof | 东北师范大学 | 2020-09-01 | — | — | CN | disclosed |
| US-20200095358-A1 | COPOLYMER AND OPTICAL FILM USING SAME | TOSOH CORPORATION (JP) | 2020-03-26 | — | — | US | disclosed |
| EP-3553097-A1 | COPOLYMER AND OPTICAL FILM USING SAME | Tosoh Corporation (JP) | 2019-10-16 | — | — | EP | disclosed |
| EP-2588480-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF& xA; | SANOFI (FR) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-04-11 | — | — | US | disclosed |
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-04-11 | — | — | US | disclosed |
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-04-11 | — | — | US | disclosed |
| US-20120231330-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011161537-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161537-A2 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | WO | disclosed |
| US-20100035146-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2120279-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCN1, HCN2 | NFE2L2 2896/4885ENPP2 849/4885PTGS1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.